Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: A prospective cohort study

• Published in: PloS one 2020-08, Vol.15 (8), p.e0237011-e0237011
• Main Authors: Ramos-Martínez, Antonio, Pericàs, Juan Manuel, Fernández-Cruz, Ana, Muñoz, Patricia, Valerio, Maricela, Kestler, Martha, Montejo, Miguel, Fariñas, M. Carmen, Sousa, Dolores, Domínguez, Fernando, Ojeda-Burgos, Guillermo, Plata, Antonio, Vidal, Laura, Miró, José María, Oury, Cécile
• Format: Article
• Language: English
• Subjects: Ampicillin; Antibiotics; Bacterial endocarditis; Biology and Life Sciences; Ceftriaxone; Cohort analysis; Creatinine; Drug therapy; Endocarditis; Enterococcal infections; Enterococcus faecalis; Hospitals; Medical prognosis; Medicine and Health Sciences; Mortality; Patients; Penicillin; Signs and symptoms; Software; Supervision; Surgery; Survival analysis; Testing
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0237011

Enterococcus faecalis infective endocarditis (EFIE) is a severe disease of increasing incidence. The objective was to analyze whether the outcome of patients with native valve EFIE (NVEFIE) treated with a short course of ampicillin plus ceftriaxone (4wAC) was similar to patients treated according to international guidelines (6wAC). Between January 2008 and June 2018, 1,978 consecutive patients with definite native valve IE were prospectively included in a national registry. Outcomes of patients with NVEFIE treated with 4wAC were compared to those of patients who received 6wAC. Three hundred and twenty-two patients (16.3%) had NVEFIE. One hundred and eighty-three (56.8%) received AC. Thirty-nine patients (21.3%) were treated with 4wAC for four weeks and 70 patients (38.3%) with 6wAC. There were no differences in age or comorbidity. Patients treated 6wAC presented a longer duration of symptoms before diagnosis (21 days, IQR 7-60 days vs. 7 days, IQR 1-22 days; p = 0.002). Six patients presented perivalvular abscess and all of these received 6wAC. Surgery was performed on 14 patients (35.9%) 4wAC and 34 patients (48.6%) 6wAC (p = 0.201). In-hospital mortality, one-year mortality and relapses among 4wAC and 6wAC patients were 10.3% vs. 11.4% (p = 0.851); 17.9% vs. 21.4% (p = 0.682) and 5.1% vs. 4.3% (p = 0.833), respectively. In conclusion, a four-week course of AC may be considered as an alternative regimen in NVEFIE, notably in patients with shorter duration of symptoms and those without perivalvular abscess. These results support the performance of a randomized clinical trial to evaluate the efficacy of this short regimen.